Plain-English translation of NCT07708714 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Sickle Cell Disease research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing hydroxyurea, a medication that helps prevent painful episodes in children with sickle cell anemia. Researchers want to find the best dose—whether a fixed amount or a dose that increases gradually—to safely reduce pain crises and improve blood counts in children living in Uganda, where malaria is also common.
Hydroxyurea works well for sickle cell pain, but doctors aren't sure what the safest and most effective dose is for children in Africa, especially those who may also have malaria. This trial will help doctors find the right dose so more children can benefit from this treatment.
You likely qualify if…
You likely don't qualify if…
You will visit the clinic every three months for check-ups, blood tests, and health assessments while taking the medication. If you're in the new group, your dose will be gradually increased over time to find your best dose; if you're already taking it, you'll continue at your optimized dose. The study team will monitor your blood counts, watch for any side effects, and collect information about pain episodes and other sickle cell complications over the long term.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
Uganda